Share this article
BILTHOVEN, Netherlands, Feb. 19, 2021 /PRNewswire/
Intravacc, a world leader in translational research and development of vaccines, today announced that its new modern pilot production plant will soon be operational. In addition, Intravacc is leading a consortium that will start with the concept design (phase I) of a so-called Multi Purpose Vaccine Production Plant (MPVPP). In times of emergency, this factory will be able to quickly and safely produce sufficient doses of vaccine specifically for the Netherlands.
Globally, Bilthoven has long been a household name in the field of vaccine development for infectious diseases. Over the years, many vaccine production and technology processes have been transferred from Bilthoven to governments and companies worldwide through technology transfer agreements.
Dutch Intravacc starts concept design for multifunctional, high-capacity vaccine plant for national requirement
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Dutch Intravacc starts concept design for multifunctional, high-capacity vaccine plant for national requirement
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
European Commission grants Vico Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia
News provided by
Share this article
a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the European Commission (EC) has granted orphan drug designation for VO659, Vico s investigational antisense oligonucleotide therapy for the treatment of Spinocerebellar Ataxia (SCA). The orphan designation was based on a positive opinion from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). Vico previously received orphan drug designation for VO659 in Huntington Disease. Spinocerebellar Ataxias
IME Medical Electrospinning and STENTiT enter into development cooperation on resorbable endovascular support grafts to regenerate vascular tissue
News provided by
Share this article
Share this article
WAALRE, Netherlands, Feb. 10, 2021 /PRNewswire/ IME Medical Electrospinning, a global leader in electrospun medical devices, today announced that it has entered into a collaboration with Dutch medical device company STENTiT, to join forces in the further development and production of regenerative
). These resorbable fibrous implants hold the promise to rebuild a new blood vessel inside the existing artery, by exploiting the natural healing response of the body.
IME s technological solutions enable the manufacturing of innovative devices like STENTiT s endovascular support grafts, which are aimed to mimic the natural human extracellular matrix for implants in the human body in nanometer and micrometer format. Human cells rebuild these matrices leading to new body tissue. This